A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia

被引：0
|
作者：
Ghobrial, Irene M.
Gertz, Morie A.
LaPlant, Betsy
Camoriano, John [3 ]
Hayman, Suzanne R.
Lacy, Martha Q.
Chuma, Stacey
Sheehy, Patricia [1 ]
Harris, Brianna
Leduc, Renee
Rourke, Meghan
Ansell, Stephen M. [2 ]
DeAngelo, Daniel J. [1 ]
Dispenzieri, Angela
Bergsagel, Leif [3 ]
Reeder, Craig B. [3 ]
Anderson, Kenneth C.
Richardson, Paul
Treon, Steven
Witzig, Thomas E. [2 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Mayo Clin, Coll Med, Rochester, MN USA
[3] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [21] Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia
    Ghobrial, I. M.
    Redd, R.
    Armand, P.
    Banwait, R.
    Boswell, E.
    Chuma, S.
    Huynh, D.
    Sacco, A.
    Roccaro, A. M.
    Perilla-Glen, A.
    Noonan, K.
    MacNabb, M.
    Leblebjian, H.
    Warren, D.
    Henrick, P.
    Castillo, J. J.
    Richardson, P. G.
    Matous, J.
    Weller, E.
    Treon, S. P.
    LEUKEMIA, 2015, 29 (12) : 2338 - 2346
  • [22] mTOR inhibition for relapsed or refractory Hodgkin lymphoma: Promising single agent activity with Everolimus (RAD001)
    Johnston, Patrick B.
    Ansell, Steven M.
    Colgan, Josph P.
    Habermann, Thomas M.
    Inwards, David J.
    Micallef, Lvana N. M.
    Porrata, Luis F.
    Reeder, Craig B.
    Roy, Vivek
    LaPlant, Betsy R.
    Wilzig, Thomas E.
    BLOOD, 2007, 110 (11) : 753A - 753A
  • [23] A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    T E Witzig
    C B Reeder
    B R LaPlant
    M Gupta
    P B Johnston
    I N Micallef
    L F Porrata
    S M Ansell
    J P Colgan
    E D Jacobsen
    I M Ghobrial
    T M Habermann
    Leukemia, 2011, 25 : 341 - 347
  • [24] A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    Witzig, T. E.
    Reeder, C. B.
    LaPlant, B. R.
    Gupta, M.
    Johnston, P. B.
    Micallef, I. N.
    Porrata, L. F.
    Ansell, S. M.
    Colgan, J. P.
    Jacobsen, E. D.
    Ghobrial, I. M.
    Habermann, T. M.
    LEUKEMIA, 2011, 25 (02) : 341 - 347
  • [25] A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
    Johnston, Patrick B.
    Inwards, David J.
    Colgan, Joseph P.
    Laplant, Betsy R.
    Kabat, Brian F.
    Habermann, Thomas M.
    Micallef, Ivana N.
    Porrata, Luis F.
    Ansell, Stephen M.
    Reeder, Craig B.
    Roy, Vivek
    Witzig, Thomas E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (05) : 320 - 324
  • [26] Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenstrom Macroglobulinemia
    Ghobrial, I. M.
    Roccaro, A. M.
    Matous, J.
    Padmanabhan, W.
    Badros, A.
    Schlossman, R.
    Chuma, S.
    Leduc, R.
    Nelson, M.
    O'Connor, K.
    Sam, A.
    Harris, B.
    Soumerai, J.
    Warren, D.
    Birner, A.
    Munshi, N. C.
    Treon, S. P.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S83 - S84
  • [27] Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).
    Ghobrial, Irene M.
    Leleu, Xavier
    Rubin, Nancy
    Xie, Wanling
    Hong, Fangxin
    Chuma, Stacey
    Leduc, Renee
    Nelson, Marybeth
    O'Connor, Kelly
    Sam, Amy
    Harris, Brianna
    Warren, Diane
    Sportelli, Peter
    Treon, Steven P.
    Weller, Edie
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2008, 112 (11) : 372 - 372
  • [28] Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    Harris, Loleta
    Urbauer, Diana
    McConkey, David J.
    Dickstein, Rian J.
    Cheng, Tiewei
    Grossman, H. Barton
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2863 - 2873
  • [29] EFFECTS OF MTOR INHIBITOR EVEROLIMUS (RAD001) ON BLADDER CANCER CELLS
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    McConkey, David J.
    Grossman, H. Barton
    JOURNAL OF UROLOGY, 2009, 181 (04): : 406 - 406
  • [30] SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).
    Garland, Linda L.
    Ou, Sai-Hong
    Moon, James
    Mack, Philip C.
    Testa, Joseph
    Tsao, Anne S.
    Wozniak, Antoinette J.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345